[go: up one dir, main page]

UA83077C2 - Фармацевтическая композиция, содержащая селективный агонист имидазолинового рецептора i1 моксонидин и блокатор рецептора ангиотензина ii эпросартан - Google Patents

Фармацевтическая композиция, содержащая селективный агонист имидазолинового рецептора i1 моксонидин и блокатор рецептора ангиотензина ii эпросартан

Info

Publication number
UA83077C2
UA83077C2 UAA200604846A UAA200604846A UA83077C2 UA 83077 C2 UA83077 C2 UA 83077C2 UA A200604846 A UAA200604846 A UA A200604846A UA A200604846 A UAA200604846 A UA A200604846A UA 83077 C2 UA83077 C2 UA 83077C2
Authority
UA
Ukraine
Prior art keywords
receptor
pharmaceutical compositions
moxonidine
angiotensin
eprosartan
Prior art date
Application number
UAA200604846A
Other languages
English (en)
Ukrainian (uk)
Inventor
Доминик Баум
Герхард-Вильгельм Биленберг
Бернд Бьодекер
Дирк Тормелен
Original Assignee
Солвей Фармасьютикалс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Гмбх filed Critical Солвей Фармасьютикалс Гмбх
Publication of UA83077C2 publication Critical patent/UA83077C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описана фармацевтическая композиция, содержащая селективный агонист имидазолинового рецептора в комбинации с блокаторами рецептора ангиотензина II. В частности в заявке описана фармацевтическая композиция, которая содержит моксонидин и эпросартанмезилат, и ее производное, для приготовления лекарственного средства для лечения гипертензии, особенно у пациентов, которые уже страдают от диабета типа II или склонны к развитию диабета типа II.
UAA200604846A 2003-10-10 2004-10-07 Фармацевтическая композиция, содержащая селективный агонист имидазолинового рецептора i1 моксонидин и блокатор рецептора ангиотензина ii эпросартан UA83077C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03103763 2003-10-10

Publications (1)

Publication Number Publication Date
UA83077C2 true UA83077C2 (ru) 2008-06-10

Family

ID=34486329

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200604846A UA83077C2 (ru) 2003-10-10 2004-10-07 Фармацевтическая композиция, содержащая селективный агонист имидазолинового рецептора i1 моксонидин и блокатор рецептора ангиотензина ii эпросартан

Country Status (19)

Country Link
US (2) US20050143435A1 (ru)
EP (1) EP1673107B1 (ru)
JP (1) JP4829115B2 (ru)
KR (1) KR101137084B1 (ru)
CN (1) CN100453117C (ru)
AT (1) ATE390148T1 (ru)
AU (1) AU2004283047B2 (ru)
BR (1) BRPI0415198A (ru)
CA (1) CA2541867C (ru)
DE (1) DE602004012763T2 (ru)
ES (1) ES2304624T3 (ru)
IL (1) IL174762A (ru)
MX (1) MXPA06004029A (ru)
NO (1) NO335735B1 (ru)
PL (1) PL1673107T3 (ru)
RU (1) RU2362561C2 (ru)
UA (1) UA83077C2 (ru)
WO (1) WO2005039639A2 (ru)
ZA (1) ZA200601804B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
US8685452B2 (en) * 2006-06-16 2014-04-01 Lek Pharmaceuticals D.D. Pharmaceutical composition
EP2018885B1 (en) 2007-07-25 2011-02-09 Schott forma vitrum ag Application device
WO2009058950A2 (en) * 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
KR101667081B1 (ko) * 2009-06-30 2016-10-17 사노피 이르베사르탄 및 암로디핀을 포함하는 고형의 고정 용량 제약 조성물, 그의 제법 및 그의 치료학적 용도
CN102850331B (zh) * 2012-09-17 2015-05-20 符爱清 一种化合物的制备方法
MD4412C1 (ru) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Использование 4-({2-бутил-5-[2-карбокси-2-(тиофен-2-илметил)ет-1-ен-1-ил]-1H-имидазол-1-ил}метил)бензойной кислоты для улучшения эластичности сосудов в профилактике осложнений гипертонического генеза
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
RU2734281C1 (ru) * 2019-06-11 2020-10-14 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Композиция для лечения артериальной гипертензии и ассоциированных с ней патологий сердечно-сосудистой системы
EP3986412A4 (en) 2019-06-21 2023-11-15 The Broad Institute, Inc. AGENTS TO REVERSE TOXIC PROTEINOPATHIES
GB202006074D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
WO2025002914A1 (en) 2023-06-26 2025-01-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Antagonists of the imidazoline-1 receptor for use in the prevention and/or treatment of an autoinflammatory or autoimmune disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5354867A (en) * 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
JP2707390B2 (ja) * 1992-05-22 1998-01-28 壽製薬株式会社 シクロヘプトイミダゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2229123A1 (en) * 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
HU0200980D0 (ru) * 2002-03-14 2002-05-29 Gabor S Pal Dr
WO2004024720A1 (en) * 2002-09-11 2004-03-25 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
EP1673107A2 (en) 2006-06-28
RU2362561C2 (ru) 2009-07-27
MXPA06004029A (es) 2006-06-28
US20050143435A1 (en) 2005-06-30
KR101137084B1 (ko) 2012-04-24
IL174762A0 (en) 2006-08-20
CA2541867A1 (en) 2005-05-06
NO20062088L (no) 2006-07-07
RU2006115796A (ru) 2007-11-27
ATE390148T1 (de) 2008-04-15
BRPI0415198A (pt) 2006-12-05
EP1673107B1 (en) 2008-03-26
AU2004283047A1 (en) 2005-05-06
US20110229571A1 (en) 2011-09-22
WO2005039639B1 (en) 2005-09-22
IL174762A (en) 2010-11-30
CN1859924A (zh) 2006-11-08
WO2005039639A2 (en) 2005-05-06
CN100453117C (zh) 2009-01-21
JP4829115B2 (ja) 2011-12-07
HK1096293A1 (zh) 2007-06-01
PL1673107T3 (pl) 2008-06-30
NO335735B1 (no) 2015-02-02
JP2007508276A (ja) 2007-04-05
ZA200601804B (en) 2007-05-30
ES2304624T3 (es) 2008-10-16
CA2541867C (en) 2012-06-12
KR20060117912A (ko) 2006-11-17
AU2004283047B2 (en) 2009-09-17
DE602004012763D1 (de) 2008-05-08
DE602004012763T2 (de) 2009-05-07
WO2005039639A3 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
UA83077C2 (ru) Фармацевтическая композиция, содержащая селективный агонист имидазолинового рецептора i1 моксонидин и блокатор рецептора ангиотензина ii эпросартан
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
TW200730202A (en) Solid dosage form
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
MXPA06011924A (es) Dispositivo de liberacion continua base polimeros.
MX2009008534A (es) Antagonistas novedosos del receptor de glucagon.
MY162095A (en) Method of treating symptoms of hormonal variations
IL186089A0 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EP2559434A3 (en) Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
GB2454620A (en) Solid dosage form of olmesartan medoxomil and amlodipine
IL184048A0 (en) Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists
WO2008078715A1 (ja) Ｉｌ－６アンタゴニストを有効成分とする炎症性筋疾患治療剤
WO2007095113A3 (en) Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
TW200722088A (en) Diabetes remedy
UA98472C2 (ru) Применение агониста рецептора epo человека для лечения интолерантности к глюкозе
GB0111220D0 (en) Restricting reinstatement of drug use
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
DK1503764T3 (da) 5-HT4-receptor-antagonister til behandling af hjertesvigt
TNSN07291A1 (en) Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases